

### Opioids, Aspirin, NSAIDs, sCOX-2 Inhibitors & Breast Cancer Recurrence: Pharmacoepidemiology studies using DBCG data

Deirdre Cronin Fenton Associate Professor, Ph.D. <u>dc@clin.au.dk</u>

**DBCG Annual Meeting, January 2016** 

KEA.AU.DK

**AARHUS UNIVERSITY HOSPITAL** 





# "Pharmacoepidemiology"

• The study of drug use or the effect of drugs in large populations

- Several pharmacoepi databases in Denmark:
  - Enable compilation of longitudinal drug histories
     &
  - Linkage of prescription data to other populationbased registries in Denmark, *e.g., DBCG*




# Pharmacoepi databases in Denmark

- The Prescription Registries of the Northern and Central Danish Region (Aarhus University – AUPD ~1989+; nationwide 2005+)
- The Odense University Pharmacoepidemiological Database (OPED – 1990+, South & East Dk ~2007+)
- The Danish National Prescription Registry (DNPR) at Statistics Denmark (1995+)
- Main difference:
  - AUPD & OPED: possibility to identify drug users
  - DNPR: de-identified via Stats Dk

#### The Opinion Pages | OP-ED CONTRIBUTORS

### A Cancer Treatment in Your Medicine Cabinet?

By MICHELLE HOLMES and WENDY CHEN MAY 19, 2014



WE believe that it might be possible to treat <u>breast cancer</u> — the leading cause of female <u>cancer</u> death — with a drug that can already be found in nearly every medicine cabinet in the world: Aspirin.

In 2010, we published an observational study in The Journal of Clinical Oncology showing that women with breast cancer who took aspirin at least once a week for various reasons were 50 percent less likely to die of breast cancer. In 2012, British



### Pharmacoepi studies using DBCG – some examples








### Low-dose Aspirin, NSAIDs, Selective COX-2 Inhibitors & Breast Cancer Recurrence: a Danish population-based cohort study

<u>**Deirdre Cronin-Fenton,</u>** Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen</u>

*Epidemiology*, in press 2015 (scheduled for July 2016)

# **Epidemiological studies**



- Inconsistent findings
- Post-diagnostic aspirin = 50% reduction in breast cancer mortality?
- Pre-diagnostic aspirin use = 20% reduction?
- NSAIDs = inconsistent findings
- sCOX-2i = previous studies?
- Few adjusted for statin use




### Aim:

• To investigate the association of aspirin, NSAIDs, and sCOX-2i use, with breast cancer recurrence

### Hypothesis:

 Prescription use of these drugs is associated with a decreased rate of breast cancer recurrence compared with non-use of the drugs





# **Study Population**

- Cohort of stage I-III breast cancer patients in Denmark
- Diagnosed 1996-2008 & registered in DBCG
- Follow-up for breast cancer recurrence in the DBCG registry (*i.e.,* local, regional, distant recurrent disease or contralateral breast cancer)
- 10 years of follow-up or through 01/01/2013





# Prescription drugs:

### **Exposure and Confounder definition**

### Low-dose aspirin, NSAIDs, sCOX2 inhibitors

- >=1 prescription each year, updated daily & lagged by one year
- "New users": >=5 years prescription history, no pre-diagnostic use
- **Dose-response:** number of prescriptions
- **Pre-diagnostic use:** women with >=2 years prescription history
- **Comedications:** post-diagnostic time-varying use of simvastatin & pre-diagnosis HRT



# **Statistical Analyses**

 Crude and adjusted Cox proportional hazards regression models with time-varying drug exposure updated yearly & lagged by one year

- Sensitivity analyses:
  - Drug exposure lagged by two years
  - >=2 prescriptions
- Stratified analyses (stage & ER status)
- Site of recurrence



### Results

- N=34,188 breast cancer patients
- 17% aspirin users (>=1 prescription)
- 42% NSAIDs users
- 17% sCOX-2 inhibitors
- Median age = 58 years

Aspirin users (vs non-users): older, more often mastectomy NSAID users & sCOX-2i users: slightly higher proportion stage I Aspirin, NSAID, sCOX-2i users: more likely to have received simvastatin

- 5,325 recurrences in 233,130 PY
- Median follow-up = 7.1 yrs

#### Exposure

HR (95% CI)

#### Aspirin (ref non-use)

Aspirin use 1-3 Aspirin >3 Aspirin New-users Aspirin Pre-diagnostic Aspirin


#### NSAIDs (ref non-use)

NSAID use 1-5 NSAIDs 6-10 NSAIDs >10 NSAIDs New-users NSAIDs Pre-diagnostic NSAIDs

#### sCOX-2 Inhibitor (ref non-use)

.75

sCOX-2i use 1-7 sCOX-2i >7 sCOX-2i New-users sCOX-2i Pre-diagnostic sCOX-2i



1.00 (0.90, 1.11) 0.97 (0.84, 1.12) 0.99 (0.89, 1.11) 1.00 (0.81, 1.24) 0.92 (0.83, 1.02)

0.99 (0.91, 1.08) 1.00 (0.93, 1.08) 0.88 (0.77, 1.00) 0.92 (0.83, 1.02) 1.00 (0.88, 1.14) 0.86 (0.81, 0.91)

1.10 (0.99, 1.22) 1.10 (1.04, 1.16) 0.98 (0.86, 1.12) 1.20 (0.97, 1.48) 0.89 (0.83, 0.95)

1.5



#### **Original Article**

Opioids and breast cancer recurrence: A Danish population-based cohort study

Deirdre P. Cronin-Fenton PhD<sup>1,\*</sup>, Uffe Heide-Jørgensen PhD<sup>1</sup>, Thomas P. Ahern PhD<sup>2</sup>, Timothy L. Lash DSc<sup>1,3</sup>, Peer M. Christiansen MD, DMSc<sup>4,5</sup>, Bent Ejlertsen MD, PhD<sup>5,6</sup>, Per Sjøgren MD, DMSc<sup>7</sup>, Henrik Kehlet MD, PhD<sup>8</sup> and Henrik T. Sørensen MD, DMSc<sup>1</sup>

Article first published online: 24 JUL 2015 DOI: 10.1002/cncr.29532

© 2015 American Cancer Society





# Background

- Increasing opioid use
- Opioids inhibit cell-mediated immunity
- Lab models: opioids promote/negate tumour growth
- Humans: Poorer survival associated with morphinebased anaesthesia?
- The potential that opioids may exacerbate malignant disease requires clarification


### **Prescription drugs:** Exposure and Confounder definition

#### **Opioid prescriptions**

- >=1 prescription each year, updated daily & lagged by one year
  - i.e., a patient was considered exposed to opioids at a given time when she was prescribed an opioid >1 yr but <2 yrs before each assessment period</li>
- Opioid strength: *Weak opioids=* tramadol, codeine, detropropoxyphene; *Strong opioids*= all others
- Immunosuppressive effect (Sacerdote, 2006)
- Chronic long-term use: >=1 opioid prescription per month for >=6 months of the prescribing year
- Morphine equivalent dose (Jarlbaek et al, 2005)
- Comedications: post-diagnostic time-varying use of simvastatin & pre-diagnosis HRT

Exposure

HR (95% CI)





### **Strengths**

- Large size & prospective data collection
- High quality registry data
- Information on clinical factors & complete follow-up
- Outcome of recurrence rather than mortality
  - Specific effect of drugs on breast cancer, as distinct from mortality
- Adjustment for potential confounding due to simvastatin



### Limitations

- Prescription compliance
  - Redeemed prescriptions
- No information on inhospital or perioperative drug use
- Over-the-counter drug use



# **Conclusions & Perspectives**

- No evidence of an association between post-diagnostic use of opioids, aspirin, NSAIDs, of sCOX-2i prescriptions and the rate of breast cancer recurrence
- Use of pre-diagnostic aspirin, NSAIDs or sCOX2-inhibitors
   & recurrence warrants further investigation
- Important findings to the increasing numbers of people faced with decisions regarding treatment for pain



## Acknowledgements

- DBCG
- Danish Cancer Society (R73-A4284-13-S17)
- Aarhus University Research Foundation
- The Lundbeck Foundation (R167-2013-15861)
- Elvira & Rasmus Riisforts Foundation
- Susan G. Komen for Cure (CCR 13264024)
- US NIH (R01CA166825)





KEA.AU.DK




Figure courtesy of Rikke N. Pedersen



KEA.AU.DK



# Background

#### Epidemiology

Low-dose Aspirin, NSAIDs, Selective COX-2 Inhibitors & Breast Cancer Recurrence: a Danish population-based cohort study

**Deirdre Cronin-Fenton,** Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen

Epidemiology, in press 2015 (scheduled for July 2016)

- Aspirin, NSAIDs, and selective COX-2 inhibitors (sCOX-2i)
  - Analgesics, anti-inflammatories, anti-pyretics
  - Pleiotropic effects: cardiovascular disease & cancer prevention
  - Target COX-1 & COX-2, which promote angiogenesis & prevent apoptosis
  - Lab studies: drugs impede breast cancer cells growth
  - Aspirin: low-dose has anti-platelet effects; high-dose has prostaglandin inhibitory effects
  - NSAIDs & sCOX-2: anti-prostaglandin effects

Department of Clinical Epidemiology

### Pharmaco-

# epidemiologic research using the DBCG database



study



### **EPIDEMIOLOGY**

Low-dose Aspirin, NSAIDs, Selective COX-2 Inhibitors & Breast Cancer Recurrence: a Danish population-based cohort study

Deirdre Cronin-Fenton, Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Eilertsen, Henrik T Sørensen

**Epidemiology**, in press 2015 (scheduled for July 2016)